Abstract:Rumeng Gu, 1, 2, &ast Luxi Jiang, 1, &ast Ting Duan, 1 Chun Chen, 1 Shengchang Wu, 1 Deguang Mu 1 1 Department of Respiratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China; 2 Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shengchang Wu; Deguang Mu Tel +86-15869172806 ; +86-571-58593509 Email ; Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that originates from pleural mesothelial cells. In recent years, with the development of asbestos-related industries and the increase in air pollution, its incidence has been increased. The incidence of pulmonary embolism combined with sarcomatoid MPM is very low and the prognosis is extremely poor. We here report a case of a patient with long term of pleural effusion and finally diagnosed as pulmonary embolism with sarcomatoid MPM. Case: A 75-year-old male with a 30-year history of asbestos exposure was admitted to our hospital due to chest pain and difficulty in breathing after exercise. Radiologic examination revealed pleural effusion, computed tomography pulmonary angiography (CTPA) suggests pulmonary embolism, and we consider pleural effusion caused by pulmonary embolism. After anticoagulant therapy for pulmonary embolism and pleural puncture to reduce pleural effusion, the patient's symptoms improved. However, after that, the patient was still admitted to the hospital several times because of recurrent chest pain and dyspnea symptoms, and radiologic examination always showed unexplained pleural effusion. Finally, pathological and immunohistochemical examinations of the pleural biopsy specimens were performed, and the diagnosis was confirmed as sarcomatoid MPM. Conclusion: In summary, sarcomatoid MPM with pulmonary embolism is relatively rare, and the prognosis is poor. Clinicians need to be alert to its occurrence. When the first diagnosis is confirmed and the effect of targeted treatment is still not good, the possibility of other diseases should be considered. In clinical practice, pleural biopsy guided by PET-CT is a good choice for patients with sarcomatoid MPM who cannot tolerate open pleural biopsies or thoracoscopy. And patients should undergo pleural morphology and immunohistochemistry as soon as possible, which are helpful for timely diagnosis. Keywords: malignant pleural mesothelioma, pleural effusion, asbestos Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor. The prognosis is poor, with a median survival time ranging from 8 to 14 months. 1 Most cases of MPM are associated with a history of asbestos exposure, with an incubation period of 10 to 50 years or more. 2 And chrysotile, crocidolite or amosite asbestos are the three main types of asbestos that cause MPM. Occupational asbestos exposure is the most common, such as building construction workers, power station workers, electrical workers and boilermaker. 2 There are three main histological subtypes of MPM: biphasic, epithelioid and sarcomatoid. Among them, the sarcomatoid variant has the worst prognosis, with a median survival time of only 4 months. 1 , 3 There is a strong association between cancer and thrombosis. Studies have shown that 1 in 7 hospitalized cancer patients dies from pulmonary embolism. 4 However, the incidence of sarcomatoid MPM combined with pulmonary embolism is extremely low, and the prognosis is poor. The imaging findings of MPM are mostly unilateral pleural effusion, pleural mass or pleural nodules. In the early stages of the disease, 70% of patients will find pleural effusion. 5 Pulmonary embolism can also cause pleural effusion. Here, we report a case of pulmonary embolism with sarcomatoid MPM with long-term pleural effusion. A 75-year-old male patient was admitted to Zhejiang Provincial People's Hospital on 23 November 2018 after two-week-history of post-exercise dyspnea and chest pain. Physical examination revealed decreased breath sound, increased tactile fremitus on the affected side, and dullness to percussion of the left lung. Chest computed tomography (CT) showed diffuse thickening and calcification of the pleura on both sides, pleural effusion and atelectasis on the left side ( Figure 1A and B ). After hospitalization, the patient received a thor -Abstract Truncated-

Imaging evaluation of malignant pleural mesothelioma

Imaging of Malignant Pleural Mesothelioma: Pearls and Pitfalls

Development of diagnosis and treatment on malignant pleural mesothelioma

Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma

Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group

[Analysis of clinicopathological features of 68 cases of malignant pleural mesothelioma]

Malignant Pleural Mesothelioma: Comparison of X-ray Film and CT

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

CT and PET/CT in the Diagnosis of Pleural Mesothelioma

[Advances in Immunotherapy for Malignant Pleural Mesothelioma].

Advances in immunotherapy for pleural malignant mesothelioma

Diffuse malignant peritoneal mesothelioma: A review

A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion

Advances in diagnosis and management of malignant pleural mesothelioma

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors

Diagnosis and Treatment of Malignant Peritoneal Mesothelioma

Biomarker-guided Targeted and Immunotherapies in Malignant Pleural Mesothelioma

Clinical Analysis of Combined Immunotherapy in Patients with Malignant Pleural Mesothelioma

Primary Pulmonary Malignant Meningioma: A Case Report and Literature Review Focusing on Imaging Findings

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma